BWAY vs. IRMD, BFLY, SIBN, KIDS, TMCI, SMLR, CLPT, NNOX, TCMD, and DCTH
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Iradimed (IRMD), Butterfly Network (BFLY), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), Tactile Systems Technology (TCMD), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.
BrainsWay vs.
BrainsWay (NASDAQ:BWAY) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
Iradimed has higher revenue and earnings than BrainsWay. Iradimed is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.
BrainsWay has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
BrainsWay currently has a consensus target price of $13.17, indicating a potential upside of 20.35%. Iradimed has a consensus target price of $60.00, indicating a potential downside of 0.23%. Given BrainsWay's higher probable upside, research analysts clearly believe BrainsWay is more favorable than Iradimed.
30.1% of BrainsWay shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 19.0% of BrainsWay shares are owned by insiders. Comparatively, 37.1% of Iradimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Iradimed received 183 more outperform votes than BrainsWay when rated by MarketBeat users. However, 66.99% of users gave BrainsWay an outperform vote while only 64.78% of users gave Iradimed an outperform vote.
Iradimed has a net margin of 26.12% compared to BrainsWay's net margin of 3.88%. Iradimed's return on equity of 23.99% beat BrainsWay's return on equity.
In the previous week, Iradimed had 3 more articles in the media than BrainsWay. MarketBeat recorded 4 mentions for Iradimed and 1 mentions for BrainsWay. BrainsWay's average media sentiment score of 0.82 beat Iradimed's score of 0.56 indicating that BrainsWay is being referred to more favorably in the media.
Summary
Iradimed beats BrainsWay on 11 of the 16 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
This page (NASDAQ:BWAY) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BWAY Stock Alerts